Is there a role for TNF-α in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases

Journal of the American Society of Nephrology

Volumn 17, Issue 5, 2006, Pages 1243-1252

  Feldmann, Marc ^a   Pusey, Charles D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CANNABINOID; CYTOKINE; ETANERCEPT; INFLIXIMAB; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANCA ASSOCIATED VASCULITIS; ANKYLOSING SPONDYLITIS; ARTHRITIS; AUTOIMMUNITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG MECHANISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOCYTE MIGRATION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 33646378898     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005121359     Document Type: Review

References (77)

1. Oppenheim JJ, Feldmann M: Introduction to the role of cytokine in innate host defence adaptive immunity. In: Cytokine Reference, Vol. 1: Ligands, edited by Oppenheim JJ, Feldmann M, London, Academic Press, 2001, pp 3-20
2. Feldmann M, Brennan FM: Cytokines and disease. In: Cytokine Reference, Vol. 1: Ligands, edited by Oppenheim JJ, Feldmann M, London, Academic Press, 2001, pp 35-41
3. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397-440, 1996
4. Katsikis PD, Chu QC, Maini RN, Feldmann M: Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 179: 1517-1527, 1994
5. Hermann J, Hall M, Feldmann M, Brennan FM: Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 41: 1388-1397, 1998
6. Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 316: 379-385, 1987
7. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M: Inhibitory effect of TNFalpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2: 244-247, 1989
8. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, Cerami A: Antibodies to cachectin/tumor necrosis factor reduce interleukin 1beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 170: 1627-1633, 1989
9. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, et al.: Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 38: 1581-1588, 1995
10. Nordling C, Karlsson-Parra A, Jansson L, Holmdahl R, Klareskog L: Characterization of a spontaneously occurring arthritis in male DBA/1 mice. Arthritis Rheum 35: 717-722, 1992
11. Cope AP, Patel SD, Hall F, Congia M, Hubers HA, Verheijden GF, Boots AM, Menon R, Trucco M, Rijnders AW, Sonderstrup G: T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. Arthritis Rheum 42: 1497-1507, 1999
12. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89: 9784-9788, 1992
13. Hehlgans T, Pfeffer K: The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: Players, rules and the games. Immunology 115: 1-20, 2005
14. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664, 1987
15. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334: 1697-1702, 1996
16. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36: 1681-1690, 1993
17. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337: 141-147, 1997
18. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial ATTRACT Study Group. Lancet 354: 1932-1939, 1999
19. Feldmann M, Maini RN: Anti-TNFalpha therapy or rheumatoid arthritis: What have we learned? Annu Rev Immunol 19: 163-196, 2001
20. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104, 2001
21. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343: 1594-1602, 2000
22. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52: 27-35, 2005
23. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37, 2006
24. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163: 1521-1528, 1999
25. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN: Reduction of che mokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 43: 38-47, 2000
26. Feldmann M, Maini RN: TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9: 1245-1250, 2003
27. Wolfe F, Michaud K: Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-rumor necrosis factor therapy. Am J Med 116: 305-311, 2004
28. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P: Treatment with rumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32: 1213-1218, 2005
29. Day R: Adverse reactions to TNFalpha inhibitors in rheumatoid arthritis. Lancet 359: 540-541, 2002
30. Pisetsky DS, St Clair EW: Progress in the treatment of rheumatoid arthritis. JAMA 286: 2787-2790, 2001
31. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundstrom C, Bertilsson L, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, Klareskog L, Feltelius N: Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64: 1414-1420, 2005
32. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135, 1995
33. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398-1405, 1999
34. Gorman JD, Sack KE, Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346: 1349-1356, 2002
35. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 357: 1842-1847, 2001
36. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 356: 385-390, 2000
37. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group: Maintenance infliximab for Crohn's disease: The ACCENT 1 randomised trial. Lancet 359: 1541-1549, 2002
38. D'Haens G, Swijsen C, Norman M, Lemmens L, Ceuppens J, Agbahiwe H, Geboes K, Rutgeerts P: Etanercept in the treatment of active refractory Crohn's disease: A single centre pilot trial. Am J Gastroenterol 96: 2564-2568, 2001
39. Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R: An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99: 1984-1989, 2004
40. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group: TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 53: 457-465, 1999
41. van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NH: First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172: 465-469, 2005
42. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, Beckett P, Al Ali M, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST: Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax 60: 1012-1018, 2005
43. Kumar S, Boehm J, Lee JC: p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717-726, 2003
44. Clark AR, Dean JL, Saklatvala J: Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett 546: 37-44, 2003
45. Karin M, Yamamoto Y, Wang QM: The IKK NF-kappa B system: A treasure trove for drug development. Nat Rev Drug Discov 3: 17-26, 2004
46. Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfait AM, Maini RN, Feldmann M: Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 159: 6253-6259, 1997
47. Horwood NJ, Mahon T, McDaid JP, Campbell J, Mano H, Brennan FM, Webster D, Foxwell BM: Bruton's tyrosine kinase is required for lipopolysaccharide- induced tumor necrosis factor alpha production. J Exp Med 197: 1603-1611, 2003
48. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M: The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 97: 9561-9566, 2000
49. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581, 2004
50. Takemura T, Yoshioka K, Murakami K, Akano N, Okada M, Aya N, Maki S: Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch 424: 459-464, 1994
51. Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R: In situ production of TNF-a, IL-1b and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 43: 682-692, 1993
52. Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, Remuzzi G: Tumour necrosis factor induces glomerular damage in the rabbit. Am J Pathol 134: 419-459, 1989
53. Tomosugi NI, Cashman SJ, Hay H, Pusey CD, Evans DJ, Shaw A, Rees AJ: Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumour necrosis factor, and IL-1. J Immunol 142: 3083-3090, 1989
54. Lan HY, Yang N, Metz C, Mu W, Song Q, Nikolic-Paterson DJ, Bacher M, Bucala R, Atkins RC: TNF-alpha up-regulates renal MIF expression in rat crescentic glomerulonephritis. Mol Med 3: 136-144, 1997
55. Karkar AM, Tarn FW, Steinkasserer A, Kurrle R, Langner K, Scallon BJ, Meager A, Rees AJ: Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor. Kidney Int 48: 1738-1746, 1995
56. Tam FW, Smith J, Morel D, Karkar AM, Thompson EM, Cook HT, Pusey CD: Development of scarring and renal failure in a rat model of crescentic glomerulonephritis. Nephrol Dial Transplant 14: 1658-1666, 1999
57. Karkar AM, Smith J, Pusey CD: Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. Nephrol Dial Transplant 16: 518-524, 2001
58. Khan SB, Cook HT, Bhangal G, Smith J, Tam FWK, Pusey CD: Antibody blockade of TNFalpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 67: 1812-1820, 2005
59. Tam FWK, Smith J, Agarwal S, Karkar AM, Morel D, Thompson EM, Pusey CD: Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. Nephron 84: 58-66, 2000
60. Le Hir M, Haas C, Marino M, Ryffel B: Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumour necrosis factor-deficient mice. Lab Invest 78: 1625-1631, 1998
61. Timoshanko JR, Sedgwick JD, Holdsworth SR, Tipping PG: Intrinsic renal cells are the major source of tumour necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. J Am Soc Nephrol 14: 1785-1793, 2003
62. Guo G, Morrissey J, McCracken R, Tolley T, Klahr S: Contributions of angiotensin II and rumour necrosis factor-alpha to the development of renal fibrosis. Am J Physiol 277: F766-F772, 1999
63. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110: 955-963, 2002
64. Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, Cohen Tervaert JW, Jennette JC, Heeringa P: Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide. Am J Pathol 167: 47-58, 2005
65. Pfister H, Ollert M, Frohlich LF, Quintanilla-Martinez L, Colby TV, Specks U, Jenne DE: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104: 1411-1418, 2004
66. Little MA, Smyth CL, Yadav R, Ambrose L, Cook T, Nourshargh S, Pusey CD: Anti-neurrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106: 2050-2058, 2005
67. Little MA, Smyth CL, Nakada MT, Cook HT, Nourshargh S, Pusey CD: Therapeutic effect of anti-TMF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 17: 160-169, 2006
68. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C; European Vasculitis Study Group: A randomised trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibody. N Engl J Med 349: 36-44, 2003
69. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR; for the Pan-Thames Renal Research Group: Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am J Kidney Dis 41: 776-784, 2003
70. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH: Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143: 631, 2005
71. Little MA, Pusey CD: Glomerulonephritis due to ANCA-associated vasculitis: An update on approaches to management. Nephrol 10: 368-376, 2005
72. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, Gause A: Effectiveness of TNF-a blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 41: 1303-1307, 2002
73. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, Guillevin L: Efficacy of the anti-TNF-a antibody infliximab against refractory systemic vasculitides: An open pilot study on 10 patients. Rheumatology 41: 1126-1132, 2002
74. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR: Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 61: 559, 2002
75. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS: Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety. Arthritis Rheum 44: 1149-1154, 2001
76. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, Savage C, Pusey C, Jayne D: Prospective study of TNalpha blockade with Infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15: 717-721, 2004
77. The Wegener's granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352: 351-361, 2005